EU expands approval of ALK’s house dust mite pill
European regulators have expanded the scope of ALK-Abello’s Acarizax to include the treatment of adolescent patients with house dust mite-induced allergic rhinitis.
Read More
Tag: Odactra
US approval for ALK’s house dust mite pill
US regulators have approved Odactra, the first allergen extract to be administered under the tongue to treat house dust mite (HDM)-induced nasal inflammation (allergic rhinitis) in people 18 through 65 years of age.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
